Humoral immune response after different SARS-CoV-2 vaccination regimens

被引:42
|
作者
Rose, Ruben [1 ,2 ]
Neumann, Franziska [3 ]
Grobe, Olaf [3 ]
Lorentz, Thomas [3 ]
Fickenscher, Helmut [1 ,2 ]
Krumbholz, Andi [1 ,2 ,3 ]
机构
[1] Christian Albrechts Univ Kiel, Inst Infektionsmed, Campus Kiel,Brunswiker Str 4, D-24105 Kiel, Germany
[2] Univ Klinikum Schleswig Holstein, Campus Kiel,Brunswiker Str 4, D-24105 Kiel, Germany
[3] Lab Dr Krause & Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany
关键词
COVID-19; Vaccination schemes; Immunoglobulin G; Maturity process; Virus variants of concern; Virus neutralisation; ANTIBODY;
D O I
10.1186/s12916-021-02231-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The humoral immune response after primary immunisation with a SARS-CoV-2 vector vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an mRNA vaccine boost (Pfizer/BioNTech, BNT162b2; Moderna, m-1273) was examined and compared with the antibody response after homologous vaccination schemes (AZD1222/AZD1222 or BNT162b2/BNT162b2). Methods Sera from 59 vaccinees were tested for anti-SARS-CoV-2 immunoglobulin G (IgG) and virus-neutralising antibodies (VNA) with three IgG assays based on (parts of) the SARS-CoV-2 spike (S)-protein as antigen, an IgG immunoblot (additionally contains the SARS-CoV-2 nucleoprotein (NP) as an antigen), a surrogate neutralisation test (sVNT), and a Vero-cell-based virus-neutralisation test (cVNT) with the B.1.1.7 variant of concern (VOC; alpha) as antigen. Investigation was done before and after heterologous (n = 30 and 42) or homologous booster vaccination (AZD1222/AZD1222, n = 8/9; BNT162b2/BNT162b2, n = 8/8). After the second immunisation, a subgroup of 26 age- and gender-matched sera (AZD1222/mRNA, n = 9; AZD1222/AZD1222, n = 9; BNT162b2/BNT162b2, n = 8) was also tested for VNA against VOC B.1.617.2 (delta) in the cVNT. The strength of IgG binding to separate SARS-CoV-2 antigens was measured by avidity. Results After the first vaccination, the prevalence of IgG directed against the (trimeric) SARS-CoV-2 S-protein and its receptor binding domain (RBD) varied from 55-95% (AZD1222) to 100% (BNT162b2), depending on the vaccine regimen and the SARS-CoV-2 antigen used. The booster vaccination resulted in 100% seroconversion and the occurrence of highly avid IgG, which is directed against the S-protein subunit 1 and the RBD, as well as VNA against VOC B.1.1.7, while anti-NP IgGs were not detected. The results of the three anti-SARS-CoV-2 IgG tests showed an excellent correlation to the VNA titres against this VOC. The agreement of cVNT and sVNT results was good. However, the sVNT seems to overestimate non- and weak B.1.1.7-neutralising titres. The anti-SARS-CoV-2 IgG concentrations and the B.1.1.7-neutralising titres were significantly higher after heterologous vaccination compared to the homologous AZD1222 scheme. If VOC B.1.617.2 was used as antigen, significantly lower VNA titres were measured in the cVNT, and three (33.3%) vector vaccine recipients had a VNA titre < 1:10. Conclusions Heterologous SARS-CoV-2 vaccination leads to a strong antibody response with anti-SARS-CoV-2 IgG concentrations and VNA titres at a level comparable to that of a homologous BNT162b2 vaccination scheme. Irrespective of the chosen immunisation regime, highly avid IgG antibodies can be detected just 2 weeks after the second vaccine dose indicating the development of a robust humoral immunity. The reduction in the VNA titre against VOC B.1.617.2 observed in the subgroup of 26 individuals is remarkable and confirms the immune escape of the delta variant.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Humoral immune response after different SARS-CoV-2 vaccination regimens
    Ruben Rose
    Franziska Neumann
    Olaf Grobe
    Thomas Lorentz
    Helmut Fickenscher
    Andi Krumbholz
    [J]. BMC Medicine, 20
  • [2] Cellular and humoral immune response after SARS-CoV-2 vaccination in pediatric kidney recipients
    Ahlenstiel-Grunow, Thurid
    Elsner, Carina
    Dittmer, Ulf
    Pape, Lars
    [J]. PEDIATRIC TRANSPLANTATION, 2023, 27
  • [3] Cellular and Humoral Immune Response After Sars-Cov-2 Vaccination in Pediatric Kidney Recipients
    Ahlenstiel-Grunow, T.
    Elsner, C.
    Dittmer, U.
    Pape, L.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S1144 - S1145
  • [4] Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy
    Trombetta, Claudia Maria
    Marchi, Serena
    Leonardi, Margherita
    Coppola, Chiara
    Benincasa, Linda
    Marotta, Maria Giovanna
    Buonvino, Nicola
    Maes, Piet
    Stufano, Angela
    Pontrelli, Daniela
    Vasinioti, Violetta Iris
    Manenti, Alessandro
    Camero, Michele
    Montomoli, Emanuele
    Decaro, Nicola
    Lovreglio, Piero
    [J]. ACTA TROPICA, 2023, 248
  • [5] Humoral Response after SARS-CoV-2 Vaccination in Prostate Cancer Patients
    Blaszczuk, Agata
    Sikora, Dominika
    Kis, Jacek
    Stepien, Ewa
    Drop, Bartlomiej
    Polz-Dacewicz, Malgorzata
    [J]. VACCINES, 2023, 11 (04)
  • [6] Humoral Immune Response to SARS-CoV-2 in Iceland
    Gudbjartsson, Daniel F.
    Norddahl, Gudmundur L.
    Melsted, Pall
    Gunnarsdottir, Kristbjorg
    Holm, Hilma
    Eythorsson, Elias
    Arnthorsson, Asgeir O.
    Helgason, Dadi
    Bjarnadottir, Kristbjorg
    Ingvarsson, Ragnar F.
    Thorsteinsdottir, Brynja
    Kristjansdottir, Steinunn
    Birgisdottir, Kolbrun
    Kristinsdottir, Anna M.
    Sigurdsson, Martin I.
    Arnadottir, Gudny A.
    Ivarsdottir, Erna V.
    Andresdottir, Margret
    Jonsson, Frosti
    Agustsdottir, Arna B.
    Berglund, Jonas
    Eiriksdottir, Berglind
    Fridriksdottir, Run
    Gardarsdottir, Elisabet E.
    Gottfredsson, Magnus
    Gretarsdottir, Olafia S.
    Gudmundsdottir, Steinunn
    Gudmundsson, Kjartan R.
    Gunnarsdottir, Thora R.
    Gylfason, Arnaldur
    Helgason, Agnar
    Jensson, Brynjar O.
    Jonasdottir, Aslaug
    Jonsson, Hakon
    Kristjansson, Thordur
    Kristinsson, Karl G.
    Magnusdottir, Droplaug N.
    Magnusson, Olafur T.
    Olafsdottir, Lovisa B.
    Rognvaldsson, Solvi
    le Roux, Louise
    Sigmundsdottir, Gudrun
    Sigurdsson, Asgeir
    Sveinbjornsson, Gardar
    Sveinsdottir, Kristin E.
    Sveinsdottir, Maney
    Thorarensen, Emil A.
    Thorbjornsson, Bjarni
    Thordardottir, Marianna
    Saemundsdottir, Jona
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1724 - 1734
  • [7] Humoral immune response to SARS-CoV-2 vaccination in MS patients treated with rituximab
    Torgauten, H. M.
    Cox, R. J.
    Myhr, K. -M.
    Langeland, N.
    Onyango, T. B.
    Torkildsen, O.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 775 - 775
  • [8] Poliovirus Vaccination Induces a Humoral Immune Response That Cross Reacts With SARS-CoV-2
    Comunale, Brittany A.
    Engineer, Lilly
    Jiang, Yong
    Andrews, John C.
    Liu, Qianna
    Ji, Lyuqing
    Yurkovich, James T.
    Comunale, Roderick A.
    Xie, Qiyi
    [J]. FRONTIERS IN MEDICINE, 2021, 8
  • [9] Humoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant Recipients
    Timmermann, Lea
    Globke, Brigitta
    Lurje, Georg
    Schmelzle, Moritz
    Schoening, Wenzel
    Oellinger, Robert
    Pratschke, Johann
    Eberspaecher, Bettina
    Drosten, Christian
    Hofmann, Joerg
    Eurich, Dennis
    [J]. VACCINES, 2021, 9 (12)
  • [10] Humoral immune response after SARS-CoV-2 vaccination in cladribine-treated multiple sclerosis patients
    Mimpen, M.
    Kreiter, D.
    Kempkens, T.
    Knippenberg, S.
    Hupperts, R.
    Gerlach, O.
    [J]. VACCINE: X, 2024, 16